233266-81-4

Upstream product

• 108-24-7 acetic anhydride 
• 233266-78-9 3,5-di-O-benzyl-4-C-ethynyl-1,2-O-isopropylidene-D-ribo-pentofuranose 
• 233266-76-7 (3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxole-5-carbaldehyde 
• 153186-10-8 ((3aR,5R,6S,6aR)-6-(benzyloxy)-5-((benzyloxy)methyl)-2,2-dimethyltetrahydrofuro[2,3-d][1,3]dioxol-5-yl)methanol 
• 233266-77-8 3,5-di-O-benzyl-4-C-(2,2-dibromoethenyl)-1,2-O-isopropylidene-α-D-ribo-pentofuranose 

Downstream Products

• 233266-84-7 1-(2-O-acetyl-3,5-di-O-benzyl-4-C-ethynyl-β-D-ribo-pentofuranosyl)uracil 
• 1048374-27-1 1-((2R,3R,4S,5R)-4-(benzyloxy)-5-((benzyloxy)methyl)-5-ethynyl-3-hydroxytetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione 
• 306305-03-3 1-(3,5-di-O-benzyl-4-C-ethynyl-β-D-arabino-pentofuranosyl)uracil 
• 233266-83-6 1-(2-O-acetyl-3,5-di-O-benzyl-4-C-ethynyl-β-D-ribo-pentofuranosyl)thymine 

Relevant academic research and scientific papers

Synthesis of 4'-C-ethynyl-beta-D-arabino- and 4'-C-ethynyl-2'-deoxy-beta- D-ribo-pentofuranosyl pyrimidines, and their biological evaluation.

4'-C-Ethynyl-beta-D-arabino-pentofuranosyl thymine (14) and cytosine (16), and 4'-C-ethynyl-2'-deoxy-beta-D-ribo-pentofuranosyl thymine (25) and cytosine (27) were synthesized by properly protected 4'-C-hydroxy-methyl-3,5-di-O-benzyl-alpha-D-ribo-pentofur

Purine nucleoside compound and application thereof

The invention provides a purine nucleoside compound as shown in a general formula (I) or pharmaceutically acceptable salts, crystalline hydrates or solvates thereof, a pharmaceutical composition containing the compound and application of the purine nucleoside compound in preparation of antiviral drugs. The therapeutically effective amount of the compound represented by the general formula (I), orpharmaceutically acceptable salts, crystalline hydrates and solvates thereof, or pharmaceutical compositions provided by the invention can be used alone or combined with one or more other antiviral drugs for alleviating or treating viral infections. The antiviral nucleoside provided by the invention has significant anti-HBV activity and a novel structure, and is expected to be developed into a novel nucleoside hepatitis B treatment drug.

4′-C-ethynyl pyrimidine nucleoside compounds and pharmaceutical compositions

The invention provides 4′-C-ethynyl pyrimidine nucleosides (other than 4′-C-ethynylthymidine) represented by formula [I]: wherein B represents a base selected from the group consisting of pyrimidine and derivatives thereof; X represents a hydrogen atom or